Contribution of the FeoB transporter to Streptococcus suis virulence

The contribution of iron transporter systems encoded by feo genes to the pathogenic traits of streptococci is largely unknown, despite the fact that those systems are required for the full virulence of several gram-negative bacterial species. In this work, we show that the swine pathogen and zoonotic agent Streptococcus suis has a feoAB operon similar to that encoding an iron transporter system in Escherichia coli. Electrophoretic mobility assays and transcriptional analyses confirmed that the expression of S. suis feo genes is under the negative control of the ferric uptake regulator (Fur) protein. In vivo trials in mice using a feoB defective mutant strain were carried out to investigate the contribution of this gene to the virulence of S. suis. The results showed that the median lethal dose (LD50) of the mutant was approximately 10-fold higher than that of the wild-type parent strain. These data suggest that the Feo metal transporter plays a significant role in streptococcal infectious disease. This is in contrast to previous results reported for this same gene in other gram-positive bacterial species. [Int Microbiol 2009; 12(2):137-141

Arsenic concentrations in seagrass around the Mediterranean coast and seasonal variations

Arsenic’s occurrence in the environment could be due to human activities as well as to natural sources. In this study, Posidonia oceanica and Cymodocea nodosa are collected in 84 sites around the Mediterranean basin. In addition, both seagrass are collected monthly, in two sites (Calvi in Corsica and Salammbô in Tunisia). Arsenic concentrations in C. nodosa present seasonal variations in relation with spring phytoplankton blooms. For both species arsenic concentration is higher in the vicinity of geological sources (mining), lagoon outlets and industrial activities. Moreover, Mediterranean islands (Balearic, Sardinia, Corsica, Malta, Crete and Cyprus) and the Southern basin coastline exhibit lower concentrations in Arsenic than the rest of the Mediterranean basin. The wide spread distribution of these two species would encourage their use in a global monitoring network devoted to Arsenic contamination.peer-reviewe

Knowledge and attitudes of primary health care physicians and nurses with regard to population screening for colorectal cancer in Balearic Islands and Barcelona

<p>Abstract</p> <p>Background</p> <p>Primary health care (PHC) professionals play a key role in population screening of colorectal cancer. The purposes of the study are: to assess knowledge and attitudes among PHC professionals with regard to colorectal cancer screening, as well as the factors that determine their support for such screening.</p> <p>Methods</p> <p>Questionnaire-based survey of PHC physicians and nurses in the Balearic Islands and in a part of the metropolitan area of Barcelona.</p> <p>Results</p> <p>We collected 1,219 questionnaires. About 84% of all professionals believe that screening for colorectal cancer by fecal occult blood test (FOBT) is effective. Around 68% would recommend to their clients a colorectal cancer screening program based on FOBT and colonoscopy. About 31% are reluctant or do not know. Professionals perceive the fear of undergoing a colonoscopy as the main obstacle in getting patients to participate, and the invasive nature of this test is the main reason behind their resistance to this program. The main barriers to support the screening program among PHC professionals are lack of knowledge (nurses) and lack of time (physicians). On multivariate analysis, the factors associated with reluctance to recommend colorectal cancer screening were: believing that FOBT has poor sensitivity and is complicated; that colonoscopy is an invasive procedure; that a lack of perceived benefit could discourage client participation; that only a minority of clients would participate; thinking that clients are fed up with screening tests and being unaware if they should be offered something to ensure their participation in the programme.</p> <p>Conclusions</p> <p>Two in every three PHC professionals would support a population screening program for colorectal cancer screening. Factors associated with reluctance to recommend it were related with screening tests characteristics as sensitivity and complexity of FOBT, and also invasive feature of colonoscopy. Other factors were related with patients' believes.</p

Global phylogeography and ancient evolution of the widespread human gut virus crAssphage

Microbiomes are vast communities of microorganisms and viruses that populate all natural ecosystems. Viruses have been considered to be the most variable component of microbiomes, as supported by virome surveys and examples of high genomic mosaicism. However, recent evidence suggests that the human gut virome is remarkably stable compared with that of other environments. Here, we investigate the origin, evolution and epidemiology of crAssphage, a widespread human gut virus. Through a global collaboration, we obtained DNA sequences of crAssphage from more than one-third of the world's countries and showed that the phylogeography of crAssphage is locally clustered within countries, cities and individuals. We also found fully colinear crAssphage-like genomes in both Old-World and New-World primates, suggesting that the association of crAssphage with primates may be millions of years old. Finally, by exploiting a large cohort of more than 1,000 individuals, we tested whether crAssphage is associated with bacterial taxonomic groups of the gut microbiome, diverse human health parameters and a wide range of dietary factors. We identified strong correlations with different clades of bacteria that are related to Bacteroidetes and weak associations with several diet categories, but no significant association with health or disease. We conclude that crAssphage is a benign cosmopolitan virus that may have coevolved with the human lineage and is an integral part of the normal human gut virome

Global phylogeography and ancient evolution of the widespread human gut virus crAssphage

Microbiomes are vast communities of microorganisms and viruses that populate all natural ecosystems. Viruses have been considered to be the most variable component of microbiomes, as supported by virome surveys and examples of high genomic mosaicism. However, recent evidence suggests that the human gut virome is remarkably stable compared with that of other environments. Here, we investigate the origin, evolution and epidemiology of crAssphage, a widespread human gut virus. Through a global collaboration, we obtained DNA sequences of crAssphage from more than one-third of the world’s countries and showed that the phylogeography of crAssphage is locally clustered within countries, cities and individuals. We also found fully colinear crAssphage-like genomes in both Old-World and New-World primates, suggesting that the association of crAssphage with primates may be millions of years old. Finally, by exploiting a large cohort of more than 1,000 individuals, we tested whether crAssphage is associated with bacterial taxonomic groups of the gut microbiome, diverse human health parameters and a wide range of dietary factors. We identified strong correlations with different clades of bacteria that are related to Bacteroidetes and weak associations with several diet categories, but no significant association with health or disease. We conclude that crAssphage is a benign cosmopolitan virus that may have coevolved with the human lineage and is an integral part of the normal human gut virome

Aspects inédits de l'étude radiologique de Ramsès II

Two very controversial aspects of the X-rays of the Pharaoh. Ramses II, which were taken in Paris are studied by the author. One of the X-rays is a study of the nose, and the other of the thorax, especially its central region where the heart is located. Thus new light has been shed on this very important, but up to now very obscure and debated aspect.L'auteur envisage deux aspects très polémiques de l'étude radiologique du Pharaon Ramsès II réalisée lors de son séjour à Paris. Il s'agit, d'une part, de l'étude radiographique de la masse granuleuse siégeant au niveau du nez et, d'autre part, de l'étude du thorax, notamment de la région du cœur ; l'auteur apporte une lumière nouvelle sur cet aspect important et jusqu'à présent encore fort confus.LLagostera E. Aspects inédits de l'étude radiologique de Ramsès II. In: Bulletins et Mémoires de la Société d'anthropologie de Paris, XIII° Série. Tome 8 fascicule 3, 1981. pp. 331-335

The Bolton Treovance abdominal stent-graft: European clinical trial design

Endovascular aortic repair (EVAR) has emerged as a promising, less invasive alternative to conventional open surgery for the treatment of infrarenal abdominal aortic aneurysms (AAAs). In the last 20 years, the application rate of EVAR and its clinical results have significantly improved thanks to the evolution of stent-grafts and endovascular delivery systems. However, further development is still needed to reduce the incidence of complications and secondary re-interventions. The Treovance abdominal aortic stent-graft (Bolton Medical, Barcelona, Spain) is a new-generation endovascular device, developed to increase flexibility, lower profile, improve deployment and sealing mechanisms. In particular, it is provided with some innovative features as a double layer of proximal barbs (suprarenal and infrarenal) for supplemental fixation, dull barbs between modules to avoid potential leg disconnections, detachable outer sheath provided with a new-design hemostatic valve, and a double improved mechanism (slow motion and "pin and pull") for precise stent-graft deployment. A European prospective, non-randomized, multi-institutional, "first-in-human" trial (the ADVANCE trial) was conducted from March to December 2011 to assess the safety and performance of the Treovance stent-graft system before commercialization. Thirty patients with anatomically suitable non-ruptured AAAs were enrolled at five clinical sites in Italy, Spain, and Germany. EVAR was completed successfully in all patients. The stent-graft was delivered and deployed safely even in heavily angulated or calcified anatomies. No 30-day device-related complications nor deaths were observed. Preliminary experience with the Treovance abdominal stent-graft within the ADVANCE trial was satisfactory with regard to technical success and perioperative clinical results. Follow-up data are needed to assess mid- and long-term clinical outcomes, along with durability of this new-generation endovascular device